Calciphylaxis surgery

Jump to navigation Jump to search

Calciphylaxis Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Calciphylaxis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Biopsy

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Calciphylaxis surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Calciphylaxis surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Calciphylaxis surgery

CDC on Calciphylaxis surgery

Calciphylaxis surgery in the news

Blogs on Calciphylaxis surgery

Directions to Hospitals Treating Calciphylaxis

Risk calculators and risk factors for Calciphylaxis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The optimal treatment is prevention. Rigorous and continuous control of phosphate and calcium balance most probably will avoid the metabolic changes which may lead to calciphylaxis. There is no specific treatment. Of the treatments that exist, none is internationally recognised as the standard of care.

Surgery

An acceptable surgical treatment could include:

  • Urgent parathyroidectomy: The efficacy of this measure remains uncertain although calciphylaxis is associated with frank hyperparathyroidism. Urgent parathyroidectomy may benefit those patients who have uncontrollable plasma calcium and phosphorus concentrations despite dialysis. Also, cinacalcet can be used and may serve as an alternative to parathyroidectomy. The trade name of cinacalcet is Sensipar or Mimpara.
  • Patients who receive kidney transplants also receive immunosuppression. Considering lowering the dose of or discontinuing the use of immunosuppressive drugs in renal transplant patients who continue to have persistent or progressive calciphylactic skin lesions can contribute to an acceptable treatment of calciphylaxis.

References


Template:WikiDoc Sources